A large global retrospective study found GLP-1 receptor agonists were associated with significantly lower rates of dementia, Alzheimer's, Parkinson's, pancreatic cancer, lupus, and other systemic diseases in type 2 diabetes and obesity patients over 5+ years.
Dementia risk reduced by 1 percentage pointGLP-1 RA users had a 1 percentage point lower absolute risk of developing dementia compared to non-users over 5+ years (p<0.001) — a meaningful reduction given the millions of people now taking these medications.
What the researchers found
In type 2 diabetes patients, GLP-1 RA treatment was associated with significantly lower incidences of multiple systemic conditions compared to non-users (over 5+ years of follow-up):
- Dementia: Risk Difference -0.010 (p<0.001)
- Alzheimer's disease: RD -0.003 (p<0.001)
- Parkinson's disease: RD -0.002 (p<0.001)
- Pancreatic cancer: RD -0.003 (p<0.001)
- Systemic lupus erythematosus: RD -0.001 (p<0.001)
- Systemic sclerosis: RD -0.000 (p<0.001)
Bronchial asthma showed a slight increase in risk (RD 0.002, p<0.001). Similar patterns were observed in the obesity-only cohort. Additional conditions evaluated included rheumatoid arthritis, ulcerative colitis, Crohn's disease, osteoporosis, and several cancers.
Why it matters
GLP-1 medications are already among the world's most prescribed drugs for diabetes and weight loss. This study suggests their benefits may extend far beyond blood sugar and weight control — potentially reducing risk of neurodegenerative diseases, autoimmune conditions, and certain cancers. If confirmed in prospective trials, these findings could reshape how clinicians weigh the benefits of GLP-1 therapy and could expand the indications for these medications.
How the study worked
Retrospective cohort study using the Global Collaborative Network accessed through the TriNetX analytics platform. Two primary groups were compared: individuals with type 2 diabetes and individuals with obesity. Each group was divided into GLP-1 RA users vs. non-users. Incidences of 10+ systemic diseases were compared over more than 5 years of follow-up. Propensity matching methods were presumably used to balance groups (standard for TriNetX studies).
What this study cannot tell us
This is a retrospective observational study, which cannot prove causation. Despite the large sample size and global scope, residual confounding is a major concern — patients prescribed GLP-1 RAs may differ from non-users in unmeasured ways (health consciousness, access to care, overall health status). Some of the risk differences, while statistically significant, are small in absolute magnitude (e.g., SLE RD -0.001). The study does not differentiate between specific GLP-1 RAs or doses. Prospective randomized trials are needed to confirm these associations.
How to read the evidence
This is a large retrospective cohort study using a global multicenter database with over 5 years of follow-up. While the scale and consistency of findings across multiple disease categories are compelling, it is observational and subject to confounding. The study provides hypothesis-generating evidence that requires prospective validation.
When this study was published
Published in 2025, this is a very recent study that captures the expanding evidence base for GLP-1 receptor agonists' effects beyond metabolic conditions, making it highly current and relevant.
The bigger picture
The emerging picture of GLP-1 receptor agonists as broadly protective drugs — beyond glucose and weight — is one of the most exciting developments in modern medicine. Evidence is accumulating for benefits in cardiovascular disease, kidney disease, liver disease, neurodegenerative conditions, and now autoimmune diseases and cancers. The biological plausibility centers on the anti-inflammatory and cellular protective effects of GLP-1 receptor activation, which occurs in many tissues throughout the body. This study adds to the growing case for GLP-1 RAs as potential multi-system protective agents.
Questions still open
- What biological mechanisms explain GLP-1 receptor agonists' apparent protective effects across such a wide range of diseases?
- Are the neuroprotective benefits (dementia, Alzheimer's, Parkinson's) strong enough to warrant GLP-1 RA use specifically for brain protection?
- Why did bronchial asthma risk slightly increase with GLP-1 RA use, and does this represent a true adverse effect?
Common questions
Can GLP-1 medications like semaglutide prevent Alzheimer's or Parkinson's disease?
Why might GLP-1 medications affect so many different diseases?
Read the original research
Comparative outcomes of systemic diseases in people with type 2 diabetes, or obesity alone treated with and without GLP-1 receptor agonists: a retrospective cohort study from the Global Collaborative Network : Author list.
Journal of endocrinological investigation, 48(2), 483-497
Citation
Nassar, Mahmoud; Nassar, Omar; Abosheaishaa, Hazem; Misra, Anoop. (2025). Comparative outcomes of systemic diseases in people with type 2 diabetes, or obesity alone treated with and without GLP-1 receptor agonists: a retrospective cohort study from the Global Collaborative Network : Author list.. Journal of endocrinological investigation, 48(2), 483-497. https://doi.org/10.1007/s40618-024-02466-4